semaglutide risk of cancer Can obesity meds also reduce risk? A retrospective study 1.1M patients found GLP-1 drugs, especially semaglutide, significantly lower risks for multiple cancers. But not all were equale: liraglutide was linked Recent study finds that semaglutide

Seek urgent medical attention if you develop severe or persistent abdominal pain (which could indicate pancreatitis), signs of gallbladder disease, or significant vomiting that could lead to dehydration

A month's worth of weekly injections of semaglutide and tirzepatide in the United States in 2024 cost upwards of US $1,000 which puts it out of the reach of many (Blackman)

People who develop fat-adapted metabolism, learn keto food preparation, and build sustainable ketogenic eating patterns during their semaglutide course have a functional maintenance strategy available when they eventually taper off

investment in Korea for drug development, research Novo, Lilly raise concerns over Korea's plan to classify GLP-1 obesity drugs as misuse-prone Lilly Korea deepens Korea investment but flags launch risks for new drugs Kim Eun-young [email protected]

Clinical Pearl: Ideal Candidates for Combination Therapy Patients that will greatly benefit from L-carnitine adjunctive therapy: Report persistent fatigue despite adequate weight loss on GLP-1 therapy alone Demonstrate signs of muscle loss or declining lean body mass during treatment Have plateaued in their weight loss despite medication optimization Present with metabolic syndrome features beyond elevated BMI (dyslipidemia, insulin resistance) Engage in regular physical activity and seek enhanced athletic performance alongside weight management Monitoring Parameters Regular assessment should include: Weight and body composition measurements every 4-6 weeks Lipid panel and HbA1c at 3-month intervals Liver function tests at baseline and 6 months (L-carnitine may affect hepatic fat metabolism) Patient-reported outcomes: energy levels, GI tolerability, exercise capacity Prescribing Patterns & Updates Growing Interest in Combination Metabolic Therapies Clinical practice patterns indicate increasing adoption of adjunctive therapies alongside GLP-1 medications